Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Gross Margin (2016 - 2025)

Historic Gross Margin for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to 42.92%.

  • Immucell's Gross Margin rose 165800.0% to 42.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.93%, marking a year-over-year increase of 144300.0%. This contributed to the annual value of 29.97% for FY2024, which is 78300.0% up from last year.
  • As of Q3 2025, Immucell's Gross Margin stood at 42.92%, which was up 165800.0% from 43.72% recorded in Q2 2025.
  • Over the past 5 years, Immucell's Gross Margin peaked at 51.72% during Q1 2022, and registered a low of 8.73% during Q1 2023.
  • Moreover, its 5-year median value for Gross Margin was 38.75% (2021), whereas its average is 35.75%.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -430000bps in 2023, then surged by 232500bps in 2025.
  • Over the past 5 years, Immucell's Gross Margin (Quarter) stood at 47.04% in 2021, then crashed by -46bps to 25.37% in 2022, then decreased by -7bps to 23.48% in 2023, then skyrocketed by 56bps to 36.53% in 2024, then increased by 17bps to 42.92% in 2025.
  • Its Gross Margin was 42.92% in Q3 2025, compared to 43.72% in Q2 2025 and 41.58% in Q1 2025.